STRS Ohio’s Lexeo Therapeutics LXEO Stock Holding History

STRS Ohio’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,800	Closed	-$28K	–	2036
2024 Q1	$28K	Buy	+1,800	New	+$28.1K	﹤0.01%	1824

Other funds holding LXEO

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DCP

D1 Capital Partners New York $11.2B AUM 15.78% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

STRS Ohio's LXEO Position: Q2 2024 in Review

STRS Ohio sold out of Lexeo Therapeutics (LXEO) in Q2 2024, closing a stake of 1,800 shares — an estimated $28K sold.

STRS Ohio first reported a position in LXEO in Q1 2024 and held it in 1 quarter. The position peaked at $28K in Q1 2024. 59 funds tracked by Wall St. Rank hold LXEO as of Q2 2024.

STRS Ohio reported no remaining Lexeo Therapeutics position as of Q2 2024 after selling out during the quarter.
STRS Ohio sold 1,800 Lexeo Therapeutics shares in Q2 2024, an estimated $28K.
STRS Ohio first reported a position in Lexeo Therapeutics in Q1 2024 and held it in 1 quarter.
STRS Ohio's Lexeo Therapeutics position peaked at $28K in Q1 2024.
59 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2024.

Based on STRS Ohio's 13F filing for Q2 2024, filed 5 Aug 2024.